Colorectal cancer surveillance in patients with inflammatory bowel disease: What ¡s new?

Guagnozzi, Danila; Lucendo, Alfredo J.

doi:10.4253/wjge.v4.i4.108

Cited by 22 publications

(17 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both HGD and LGD are risk factors for IBD-CRC, with the likelihood of finding synchronous cancer at colectomy 42% with HGD and 19% with LGD [52]. The variability in the risk of progression from LGD to HGD or cancer-ranging from 0-50%leads to the management controversy [75,76].…”

Section: Surgical Indications and Treatment Coursementioning

confidence: 99%

Colorectal cancer in inflammatory bowel disease: review of the evidence

et al. 2019

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD)-related colorectal cancer (CRC) is responsible for approximately 2% of the annual mortality from CRC overall, but 10%-15% of the annual deaths in IBD patients. IBD-related CRC patients are also affected at a younger age than sporadic CRC, and have a 5-year survival rate of 50%. Despite optimal medical treatment, the chronic inflammatory state inherent in IBD increases the risk for highgrade dysplasia and CRC, with additional input from genetic and environmental risk factors and the microbiome. Recognizing risk factors, implementing appropriate surveillance, and identifying high-risk patients is key to managing the CRC risk in IBD patients. Chemoprevention strategies exist, and studies evaluating their efficacy are underway. Once dysplasia or invasive cancer is diagnosed, appropriate surgical resection and post-operative treatment and surveillance are necessary. Here, we discuss the current state of IBD-related CRC, prevalence, risk factors, and evidence for surveillance, prophylaxis, and treatment recommendations.

show abstract

Section: Surgical Indications and Treatment Coursementioning

confidence: 99%

Colorectal cancer in inflammatory bowel disease: review of the evidence

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Subsequently, it was observed that patients who had biopsies from a lesion or a mass were found to have colorectal neoplasia, thus, the term “dysplasia-associated lesion or mass” was coined 32,33 . Random surveillance biopsies effectively samples about 1% of colonic mucosa 34,35 . Furthermore, it has been estimated that in order to detect one colorectal neoplasia, 1266 random biopsies were needed 36 .…”

Section: Surveillancementioning

confidence: 99%

Colon Cancer

Shawki

Ashburn

Signs

et al. 2018

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

Colitis-associated cancer is a relatively rare form of cancer with an unclear pathogenesis. Colitis-associated cancer serves as a prototype of inflammation-associated cancers. Advanced colonoscopic techniques are considered standard of care for surveillance in patients with long-standing colitis, especially those with other risk factors, including sclerosing cholangitis and a family history of colorectal cancer. When colitis-associated cancer is diagnosed, the standard operation involves total proctocolectomy. Restorative procedures and surveillance after colectomy require special considerations. In these contexts, new 3-dimensional human models may be used to usher in personalized medicine.

show abstract

“…IBD involves chronic inflammation of the intestinal tract and includes ulcerative colitis (UC) and Crohn's disease (CD) [1]. The risk factors of developing colorectal cancer in IBD patients include a family history of colorectal cancer, early age of onset of colitis and the concomitant presence of primary sclerosing cholangitis.…”

Section: Introductionmentioning

confidence: 99%

“…Patients suffering from inflammatory bowel disease (IBD) have an approximately 2- to 5-fold increased risk of developing colorectal cancer compared to age-matched healthy individuals. IBD involves chronic inflammation of the intestinal tract and includes ulcerative colitis (UC) and Crohn's disease (CD) [ 1 ]. The risk factors of developing colorectal cancer in IBD patients include a family history of colorectal cancer, early age of onset of colitis and the concomitant presence of primary sclerosing cholangitis.…”

Section: Introductionmentioning

confidence: 99%

Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer

et al. 2017

View full text Add to dashboard Cite

Cysteinyl leukotriene receptor 1 (CysLT1R) has been shown to be up-regulated in the adenocarcinomas of colorectal cancer patients, which is associated with a poor prognosis. In a spontaneous model of colon cancer, CysLT1R disruption was associated with a reduced tumor burden in double-mutant female mice (ApcMin/+/Cysltr1−/−) compared to ApcMin/+ littermates. In the current study, we utilized a genetic approach to investigate the effect of CysLT1R in the induced azoxymethane/dextran sulfate sodium (AOM/DSS) model of colitis-associated colon cancer. We found that AOM/DSS female mice with a global disruption of the Cysltr1 gene (Cysltr1−/−) had a higher relative body weight, a more normal weight/length colon ratio and smaller-sized colonic polyps compared to AOM/DSS wild-type counterparts. The Cysltr1−/− colonic polyps exhibited low-grade dysplasia, while wild-type polyps had an adenoma-like phenotype. The Cysltr1−/− colonic polyps exhibited significant decreases in nuclear β-catenin and COX-2 protein expression, while the normal crypts surrounding the polyps exhibited increased Mucin 2 expression. Furthermore, Cysltr1−/− mice exhibited an overall reduction in inflammation, with a significant decrease in proinflammatory cytokines, polyp 5-LOX expression and infiltration of CD45 leukocytes and F4/80 macrophages. In conclusion, the present genetic approach in an AOM/DSS model further supports an important role for CysLT1R in colon tumorigenesis.

show abstract

Colorectal cancer surveillance in patients with inflammatory bowel disease: What ¡s new?

Cited by 22 publications

References 117 publications

Colorectal cancer in inflammatory bowel disease: review of the evidence

Colorectal cancer in inflammatory bowel disease: review of the evidence

Colon Cancer

Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer

Contact Info

Product

Resources

About